Chapter 2. The Use of Living Listeria Monocytogenes as an Active Immunotherapy for the Treatment of Cancer

  1. Arsénio M. Fialho3 and
  2. Ananda M. Chakrabarty4
  1. John Rothman1,
  2. Anu Wallecha1,
  3. Paulo Cesar Maciag1,
  4. Sandra Rivera1,
  5. Vafa Shahabi1 and
  6. Yvonne Paterson2

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch2

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Rothman, J., Wallecha, A., Maciag, P. C., Rivera, S., Shahabi, V. and Paterson, Y. (2010) The Use of Living Listeria Monocytogenes as an Active Immunotherapy for the Treatment of Cancer, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch2

Editor Information

  1. 3

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 4

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. 1

    Advaxis Inc., North Brunswick, NJ, USA

  2. 2

    University of Pennsylvania Department of Microbiology, Philadelphia, PA, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528



  • Listeria monocytogenes, in cancer and listerial disease treatment;
  • recombinant L. monocytogenes - as vaccine vector;
  • Listeria LLO - Ag vaccines and endogenous immune inhibition


This chapter contains sections titled:

  • Introduction

  • Listerial Disease

  • Adaptive Immunity

  • Nonclassical Immune Functions

  • Recombinant L. Monocytogenes as a Vaccine Vector

  • Cross-Presentation and Epitope Spreading

  • Listeria LLO-AG Fusions and the Tumor Microenvironment

  • Conclusions

  • References